Adderall, Stimulants & Modafinil for ADHD: Short- & Long-Term Effects
Summary
This episode examines how stimulant medications like Adderall, Vyvanse, and Ritalin work at the neurological level to treat ADHD by modulating dopamine and norepinephrine in key brain circuits. Andrew Huberman explains why stimulants paradoxically calm hyperactivity, addresses long-term developmental effects, and covers non-stimulant alternatives including modafinil and guanfacine. The discussion also covers abuse potential, addiction risk, and the critical importance of proper diagnosis and dosing.
Key Takeaways
- Stimulants treat ADHD by improving the prefrontal cortex’s ability to coordinate other brain networks, not simply by increasing overall arousal — the goal is better signal-to-noise ratio in attention circuits.
- Adderall and Vyvanse are not the same drug: Adderall is a 3:1 mix of D- and L-amphetamine; Vyvanse is time-release D-amphetamine only (technically time-release dexedrine).
- Ritalin (methylphenidate) primarily increases dopamine, while Adderall/Vyvanse increase both dopamine and norepinephrine through three distinct mechanisms versus Ritalin’s one.
- Untreated ADHD in children carries a significantly higher risk of illicit drug use and addiction in adulthood than treated ADHD — the drugs do not appear to predispose children to addiction.
- Dosage is highly individual and unpredictable: a 300-lb male responded to 2.5 mg of Adderall daily, while two sisters required 180–240 mg daily for effect.
- The optimal treatment approach combines pharmacological and behavioral interventions — drugs alone are not considered the gold standard.
- Combining ADHD stimulants with alcohol or benzodiazepines is more harmful than taking either substance alone.
- Current evidence does not support the hypothesis that ADHD medications stunt height when used at appropriate doses during development.
- Early treatment with stimulants promotes neuroplasticity in attention circuits, potentially allowing some patients to reduce or cease medication over time.
- Up to ~75% of black-market prescription stimulants are contaminated with fentanyl, making non-prescription acquisition extremely dangerous.
Detailed Notes
Brain Circuits Involved in Attention
- The prefrontal cortex sits just behind the forehead and acts as the brain’s “orchestra conductor,” coordinating the activity of multiple parallel networks.
- It exerts top-down inhibition — actively suppressing circuits that generate distraction, impulsivity, and irrelevant internal chatter.
- Key networks involved in attention:
- Default mode network (DMN): active during mind-wandering, imagination, and self-referential thought; normally suppressed during focused tasks
- Salience network: flags important stimuli
- Dorsal attention network: directs focused, goal-directed attention
- In ADHD, the prefrontal cortex does not efficiently coordinate these networks — they tend to be hyper-connected and co-active at inappropriate times, which is why the DMN continues firing during tasks that require focus.
- ADHD is not simply a dopamine or norepinephrine deficiency; it reflects a dysregulation of how these neuromodulators tune circuit activity.
How Stimulants Work at the Synapse
Dopamine primarily reduces neural “noise” — suppressing distracting background signals from internal and external sources.
Norepinephrine primarily amplifies “signal” — boosting the salience and strength of circuits involved in attention and learning.
Together, they improve signal-to-noise ratio in attention networks.
Adderall and Vyvanse (amphetamines)
Increase dopamine and norepinephrine through three mechanisms:
- Block presynaptic dopamine and norepinephrine transporters (DAT/NET), preventing reuptake
- Disrupt VMAT2 (vesicular monoamine transporter 2), preventing repackaging of transmitters into vesicles — leading to buildup in the presynaptic terminal
- Disrupt the complex interaction between the above proteins, further increasing release
- D-amphetamine: primarily acts in the brain; drives most of the cognitive and focus effects
- L-amphetamine: primarily peripheral effects (increased heart rate, blood pressure, sweating)
- Adderall: 3:1 ratio of D- to L-amphetamine
- Vyvanse: D-amphetamine bonded to lysine amino acid → a prodrug that is slowly cleaved in the gut/bloodstream, producing timed-release D-amphetamine over 12–18 hours; reduces abuse potential; ~100 mg Vyvanse ≈ ~9 mg Adderall equivalent
Ritalin / Methylphenidate (Concerta)
Increases dopamine and norepinephrine through one mechanism:
- Blocks the dopamine transporter (DAT) and to a lesser extent the norepinephrine transporter
- Lower affinity for the noradrenergic transporter than amphetamines
- Primarily a dopamine-dominant drug, not a norepinephrine booster
- Not short-acting Adderall — it is a chemically distinct compound
- Standard onset: 20–40 minutes; duration: ~4–6 hours
Why Stimulants Calm Hyperactivity
- Counterintuitive but well-supported: stimulants don’t just sedate hyperactive children
- By increasing dopamine and norepinephrine at appropriate doses, they activate the prefrontal cortex’s coordinating function, allowing it to properly suppress over-active networks and prioritize relevant ones
- The result is desynchronization of hyperconnected circuits — reducing impulsive co-activation
- The goal is not global suppression, but proper sequential activation of networks
Neuroplasticity and Long-Term Treatment
- Elevated dopamine and norepinephrine promote neuroplasticity — strengthening synaptic connections in attention circuits
- Early treatment is designed not only to manage symptoms but to train circuits to function more efficiently, with lasting benefits even after medication cessation
- Children with ADHD treated appropriately show better long-term outcomes (academic, behavioral, substance use) than untreated peers
- PET neuroimaging studies show early treatment leads to normalization of dopamine transmission in the forebrain at lower thresholds later in life
Dosage
- Highly variable across individuals; no reliable predictive test exists
- Variation is largely driven by differences in drug-metabolizing enzymes
- General ranges seen in research (not prescriptive guidelines):
- Adderall: 10–40 mg/day
- Ritalin: 10–60 mg/day
- Vyvanse: typically 100s of mg/day (most is lysine, not active amphetamine)
- Best practice: start at the lowest effective dose, increase only as needed
- Anecdotal clinical example: a 300-lb male responded well to 2.5 mg Adderall/day; two sisters required 180–240 mg/day for effect
Long-Term Effects and Safety
Height and Growth
- Evidence does not support significant height stunting at appropriate doses
- Children with ADHD on medication actually trend toward slightly higher BMI than age-matched peers
Cardiovascular Risk
- Long-term sympathetic activation can elevate blood pressure and heart rate
- One major study showed a subtle increase in cardiovascular risk, but not enough for authors to recommend discontinuation under proper medical supervision
- Mitigation strategies: avoid smoking/vaping, engage in regular exercise, maintain appropriate dosing
Cortisol and Hormones
- Chronic sympathetic activation likely increases cortisol levels
- Timing of dosing matters for sleep: shorter-acting medications (Ritalin) may be preferable for preserving healthy cortisol rhythms (low at night)
- Limited long-term data on effects on the endocrine or reproductive systems
Addiction Potential
- Treated ADHD children have lower rates of illicit drug use and addiction in adulthood vs